Outlook Therapeutics launches LYTENAVA (bevacizumab gamma) in Germany and UK for wet AMD

Outlook Therapeutics, Inc.

Commercial launch of LYTENAVA (bevacizumab gamma) in Germany and UK announced on June 2, 2025.
Indication: treatment of wet age-related macular degeneration (wet AMD).
First approved bevacizumab gamma product for wet AMD in these two markets.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.